BioSpace News Archive

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.”

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.

Qualis Innovations Inc. currently trades under the symbol “QLIS” entered into an agreement with CIM Securities to raise up to $4,000,000 through a Series A preferred stock offering open to accredited investors.

GLO Pharma, the parent company of breakthrough subtopical skincare brand Ourself, today announces the appointment of Brent Saunders to its Board of Directors.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2022.

The Autism Science Foundation, a nonprofit organization dedicated to funding innovative autism research and supporting families facing autism, announced the recipients of the newly renamed Suzanne Wright Memorial Research Accelerator Grants.

AtomVie Global Radiopharma Inc. today announced the successful closing of its Series A financing with Avego Management, LLC.

The Larry G. Gluck Division of ALS Research, located at the Tisch MS Research Center of New York, has published research in Brain Communications identifying apolipoprotein B-100 (ApoB) as a key agent responsible for causing permanent motor disability, motor neuron degeneration, and other hallmark pathology in sporadic amyotrophic lateral sclerosis (sALS), a fatal neurodegenerative disease affecting 90% of ALS patients.

ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory indications, today announced the appointment of Peter Greenleaf to its board of directors.

AMPAC Fine Chemicals, an SK pharmteco company, adds additional pharmaceutical development and engineering capabilities with the opening of a new Complex Molecule Chemistry & Engineering Center